Literature DB >> 10363967

Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

J H Hooijberg1, H J Broxterman, M Kool, Y G Assaraf, G J Peters, P Noordhuis, R J Scheper, P Borst, H M Pinedo, G Jansen.   

Abstract

Transfection of multidrug resistance proteins (MRPs) MRP1 and MRP2 in human ovarian carcinoma 2008 cells conferred a marked level of resistance to short-term (1-4 h) exposure to the polyglutamatable antifolates methotrexate (MTX; 21-74-fold), ZD1694 (4-138-fold), and GW1843 (101-156-fold). Evidence for MRP-mediated antifolate efflux relies upon the following findings: (a) a 2-3.3-fold lower accumulation of [3H]MTX and subsequent reduced formation of long-chain polyglutamate forms of MTX; (b) reversal of MTX resistance by probenecid in both transfectants, and (c) ATP-dependent uptake of [3H]MTX in inside-out vesicles of MRP1 and MRP2 transfectants. This report provides a mechanistic basis for resistance to polyglutamatable antifolates through an MRP-mediated drug extrusion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363967

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  The use of Tris-lipidation to modify drug cytotoxicity in multidrug resistant cells expressing P-glycoprotein or MRP1.

Authors:  Ross A Davey; Mary W Davey; Karen V Cullen; Xanthe E Wells; Craig L Francis; Hua-Ming Williams; Qi Yang; Minoo J Moghaddam; Fred Widmer; Robert G Whittaker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Drug resistance in rheumatology: an area in search of investigators.

Authors:  Frank A Wollheim
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

3.  Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; Salvador Macías-Díaz; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Pamela Soto-Santillán; Beatriz Pérez-Romano; Erick A Jiménez-Herrera; Omar Guzmán-Ruiz; Alejandro Ruiz-Argüelles
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

4.  Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.

Authors:  Liqi Lai; Theresa M C Tan
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

Review 5.  ABC proteins of Leishmania.

Authors:  D Légaré; S Cayer; A K Singh; D Richard; B Papadopoulou; M Ouellette
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 6.  MRP subfamily transporters and resistance to anticancer agents.

Authors:  G D Kruh; H Zeng; P A Rea; G Liu; Z S Chen; K Lee; M G Belinsky
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

7.  Exploring the structure-activity relationships of ABCC2 modulators using a screening approach.

Authors:  Gloria Wissel; Pavel Kudryavtsev; Leo Ghemtio; Päivi Tammela; Peter Wipf; Marjo Yliperttula; Moshe Finel; Arto Urtti; Heidi Kidron; Henri Xhaard
Journal:  Bioorg Med Chem       Date:  2015-04-17       Impact factor: 3.641

8.  Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models.

Authors:  H Sun; D W Miller; W F Elmquist
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 9.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors:  P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

10.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.